Minimally Invasive Innovation in Endometriosis and Adenomyosis: Toward Fertility Preservation and Symptom Relief

other OA: gold public-domain-us
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-23 ⓘ

This editorial reviews two studies demonstrating that minimally invasive, fertility-preserving strategies for endometriosis and adenomyosis, including sclerotherapy and adenomyomectomy, effectively control symptoms while maintaining ovarian reserve and enabling subsequent pregnancy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-23 · read from full text ⓘ

This editorial reviews two studies highlighting minimally invasive, fertility-preserving strategies for managing estrogen-dependent gynecological disorders. The first study by Zhangwei et al. demonstrates that combining gonadotropin-releasing hormone agonists with lauromacrogol sclerotherapy offers superior efficacy and pain control compared to laparoscopic cystectomy while preserving ovarian reserve in patients with endometriotic cysts. The second study by Maneerat et al. reports that laparoscopic adenomyomectomy achieves sustained remission of dysmenorrhea and heavy bleeding in over 96% of women within 24 weeks, indicating a viable window for subsequent fertility planning. This paper is centrally about endometriosis and adenomyosis — specifically focusing on conservative surgical and interventional techniques aimed at symptom relief and reproductive preservation.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,466 characters · extracted from oa-doi-fallback · click to expand
Endometriosis and adenomyosis are two closely related, estrogen-dependent disorders that challenge clinicians with chronic pain, recurrence, and complex fertility implications. The two original articles featured in this issue of Gynecology and Minimally Invasive Therapy reflect the ongoing evolution of conservative, fertility-preserving strategies for these conditions. In the first study, Zhangwei et al. evaluated the combined use of a gonadotropin-releasing hormone agonist with lauromacrogol sclerotherapy for ovarian endometriotic cysts.[] Compared with conventional laparoscopic cystectomy, this minimally invasive protocol demonstrated higher overall efficacy (95% vs. 77.5%), lower recurrence rates, and superior postoperative pain control, all while preserving ovarian reserve. Although sclerotherapy is an established but less commonly adopted approach, its renewed consideration – particularly with the use of lauromacrogol – addresses a key clinical concern: The preservation of ovarian function. By integrating hormonal suppression and local sclerosis to inactivate cyst walls and prevent recurrence, this multimodal strategy provides a valuable alternative for patients at risk of diminished ovarian reserve following surgery.[,] The second study, by Maneerat et al., assessed outcomes of laparoscopic adenomyomectomy in women suffering from adenomyosis and endometriosis-related pain.[] Within 24 weeks postoperatively, more than 96% of patients achieved sustained remission of dysmenorrhea and heavy menstrual bleeding. Although pregnancy outcomes were not reported during the relatively short follow-up period, 42% of patients subsequently pursued assisted reproductive treatment, suggesting a crucial postoperative window for fertility planning. This study reaffirms that uterus-sparing surgery – when executed with precision and surgical finesse – can achieve durable symptom relief even in severe disease. Collectively, these investigations highlight an important clinical paradigm: Minimally invasive, fertility-preserving therapies can deliver substantial symptom control without compromising reproductive potential. The integration of pharmacologic modulation, image-guided intervention, and advanced laparoscopic techniques exemplifies the modern shift from radical excision toward biologic and functional preservation.[,] As minimally invasive gynecologic surgery continues to advance, individualized treatment planning – guided by disease extent, ovarian reserve, and reproductive goals – remains essential. These studies remind us that in managing endometriosis and adenomyosis, precision and restraint often yield the most meaningful outcomes for patients. Author contributions The author has made a substantial contribution to the conception, design, acquisition, analysis, or interpretation of data, drafting or revising the manuscript. The author has read and agreed to the final version of the manuscript. Data availability statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest. Acknowledgments We would like to thank all staff of the department for their support in this study. REFERENCES 1. Zhangwei S, Lie M, Yan Y, Lingling L. The impact of gonadotropin-releasing hormone agonist combined with lauromacrogol on ovarian reserve function and pain scores in patients with ovarian endometriotic cysts. Gynecol Minim Invasive Ther 2026;15:127–31.2. Frankowska K, Dymanowska-Dyjak I, Abramiuk M, Polak G. The efficacy and safety of transvaginal ethanol sclerotherapy in the treatment of endometrial cysts-a systematic review. Int J Mol Sci 2024;25:1337.3. Lavadia CM, Jeong HG, Ryu KJ, Park H. Ovarian reserve and IVF outcomes after ethanol ovarian sclerotherapy in women with endometrioma:A systematic review and meta-analysis. Reprod Biomed Online 2025;51:104840.4. Maneerat P, Lin WL, Lee CL. Postoperative outcomes on endometriosis-related pain following laparoscopic adenomyomectomy:A retrospective cohort study. Gynecol Minim Invasive Ther 2026;15:121–6.5. Chu Z, Jia L, Dai J, Wu Q, Tian F, Bai S. Effects of different treatment methods on clinical efficacy and fertility outcomes of patients with adenomyosis. J Ovarian Res 2024;17:16.6. Shats M, Zajicek M, Siedhoff MT, Meyer R. Updates on adenomyosis and fertility. Curr Opin Obstet Gynecol 2025;37:198–206.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-25T06:10:54.854274+00:00
pubmed
last seen: 2026-09-25T06:04:36.861825+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine